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Nutrition refers to the process by which a living organism ingests and digests food and uses the
nutrients therein for growth, tissue maintenance and all other functions essential to life. Food
components interact with our body at molecular, cellular, organ and system level. Nutrients
come in complex mixtures, in which the presence and concentration of single compounds as
well as their interactions with other compounds and the food matrix influence their bioavail-
ability and bioefficacy. Traditionally, nutrition research mainly concentrated on supplying
nutrients of quality to nourish populations and on preventing specific nutrient deficiencies.
More recently, it investigates health-related aspects of individual ingredients or of complete
diets, in view of health promotion, performance optimisation, disease prevention and risk
assessment. This review focuses on proteins and peptides, their role as nutrients and biomarkers
and on the technologies developed for their analysis. In the first part of this review, we provide
insights into the way proteins are currently characterised and analysed using classical and
emerging proteomic approaches. The scope of the second part is to review major applications
of proteomics to nutrition, from characterisation of food proteins and peptides, via investigation
of health-related food benefits to understanding disease-related mechanisms.
Nutriproteomics: Biomarkers: Ingredients
Proteins and peptides as ingredients and biomarkers
Proteins form a major class of macronutrients and they
participate in most biological processes in the body.
Enzymes are those proteins that catalyse virtually every
biochemical reaction involved in metabolism (e.g. the
digestive enzymes pepsin and trypsin). Proteins also ensure
structural and mechanical functions and they are involved
in cell signalling and immune response. Therefore, the
body needs relatively large amounts of proteins to ensure
proper function and to cope with the continuous synthesis
and degradation (protein turnover).
Proteins and peptides are composed of amino acids
that are arranged in a sequential fashion to form higher
structures and functions. The essential amino acids cannot
be synthesised by the body and must therefore be taken up
with the diet(1) (i.e. for adults: leucine, isoleucine, valine,
lysine, threonine, tryptophan, methionine, phenylalanine
and histidine). Food proteins differ in their amino acid
composition depending on their origin, i.e. animal or plant
source. Consequently, a balanced diet covers proteins from
complementary sources (e.g. meat, vegetables, cereals,
grains and legumes) in order to avoid amino acid defi-
ciencies. The nutritional quality of proteins is described
by the amino acid composition, digestibility and absorptive
ability(2).
Proteins, by nature, are key actors in all biological pro-
cesses in the human organism. Proteomics is a powerful
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tool for the elucidation of such molecular events related
to nutrition: it can identify and quantify bioactive proteins
and peptides, shed light on their effects at protein/peptide
level (biomarkers) and thereby addresses questions of
nutritional bioefficacy. In this paper, we will first describe
how proteins are analysed in a holistic, high-throughput
fashion; and in the second part we will review major
applications of proteomics in the nutrition field.
Proteomic technologies
Proteomics builds on a combination of several techniques
and has been propelled by technological progresses
including genome sequencing, biomolecule separation,
MS and bioinformatics. The discipline has evolved as an
analogue to genomics and has traditionally aimed at iden-
tifying all proteins present in a given sample at a given
time. Over the last two decades, proteomics has been
developed into an established technology for biomarker
discovery(3,4), clinical applications(5), disease profiling and
diagnostics(6,7), the study of protein interactions(8) and of
the dynamics of signalling pathways(9).
The proteome is highly dynamic and constantly changing
in response to environmental stimuli including nutrition.
Nutritional proteomics holds great promise to (a) profile
and characterise body and dietary proteins, including
digestion and absorption of the latter; (b) identify bio-
markers of nutritional status and health/disease conditions;
and (c) understand functions of nutrients and other dietary
factors in growth, reproduction and health(10).
The classical proteomic workflow, sometimes referred
to as bottom-up approach, combines techniques of protein
separation, protein digestion into peptides, mass spectro-
metric analysis, protein identification by comparison with
protein databases and protein quantification(11). The
development of gentle ionisation strategies such as elec-
trospray ionisation(12) and matrix-assisted laser desorption/
ionisation (MALDI)(13) MS, as well as the publication of
genome sequences of many organisms including human
were breakthrough factors for the successful development
and deployment of proteomics.
The sequence of amino acids defines the primary struc-
ture of a protein. Secondary, tertiary and quaternary
structures concern the arrangement of the amino acid chain
in space, resulting from covalent or non-covalent interac-
tions. Nowadays, the primary structures of proteins are
routinely analysed by MS. Post-translational modifications
(PTM) and protein–ligand interactions can also be eluci-
dated this way.
Protein separation on gels and columns
A major analytical challenge of proteomics is the dynamic
range of protein concentrations (e.g. estimated 1012 in
human blood)(14). Current MS-based proteomic platforms
can deliver a dynamic range of 104. This means that the
low-abundant proteome has to be addressed by depletion of
the most abundant proteins(15) or by selective enrichment
of low-abundant proteins(16–18). After protein depletion
and/or enrichment, further separation is performed at protein
and/or peptide level, based on two-dimensional (2D) gels
or on liquid chromatography (LC) or on hybrid approaches
(Gel-LC). Fig. 1 summarises the classical proteomic
workflows.
The gel strategy for protein separation offers the
advantage of visualisation of proteins, and, to some extent,
of their modifications and, therefore, it preserves the pro-
tein context. After protein separation on gel, the gel
spots are then excised, digested with trypsin and further
processed in LC-tandem MS (MS/MS) or MALDI-MS
instruments for protein identification. However, major
drawbacks of this method are that (i) hydrophobic proteins
such as membrane proteins, very basic proteins and low-
abundant proteins are not well represented on the gels
and (ii) the procedure is low throughput and difficult to
standardise and automate.
The ‘gel-free’ discovery approach for protein identifi-
cation is referred to as ‘shotgun’ analysis: here, the sample
or protein mixture is directly digested in solution. The
resulting peptide mixture is then separated on an HPLC
usually coupled online to a mass spectrometer for peptide
mass identification. The development of ultra-HPLC deli-
vers improved peptide separation(19) and column efficiency
by means of higher mass sensitivity, analytical resolution
and speed. The resolving capability of the HPLC separa-
tion can be enhanced with 2D HPLC techniques(20) that
combine ion-exchange chromatography followed by
reverse-phase HPLC.
Peptides can also be separated using gas-phase fractio-
nation, which is defined as iterative mass spectrometric
interrogations of a sample over multiple smaller mass-
to-charge (m/z) ranges. By doing so, a higher number of
unique peptides compared to the ions selected from the
wide mass range scan in standard LC-MS/MS analysis can
be addressed. Gas-phase fractionation is described as a
means to achieve higher proteome coverage than classical
LC-MS/MS analyses of a complex peptide mixture(21–23).
Protein identification by MS
Mass spectrometers identify proteins and peptides by
determination of their exact masses and by generating
information on their amino acid sequences. Today the main
ionisation methods deployed are electrospray ionisation(24)
and MALDI(25). These ion sources are combined with
various mass analysers that separate the ions by m/z. The
most popular analysers in proteomics are ion traps, triple-
quadrupoles, time-of-flight tubes, orbitrap and Fourier-
transform ion cyclotron resonance, with their specific
advantages: high sensitivity and multiple-stage fragmenta-
tion for ion traps; high selectivity for triple-quadrupoles;
high sensitivity and speed for time-of-flight. Current
top-end proteomic machines are orbitraps(26) and Fourier-
transform ion cyclotron resonance instruments(27), which
provide very high mass accuracy and resolution compared
to the other analysers. MS/MS consists of either the frag-
mentation of a selected precursor peptide ion to generate
specific fragment ions for sequence elucidation (data-
dependent acquisition); or uncoupled acquisitions of intact
and fragment masses with retrospective reconstitution of
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the parent–daughter ion context (data-independent acqui-
sition; see Emerging Technologies)(28).
Considering the amount of data generated in a single
shotgun run, search algorithms have been developed to
process the raw data automatically and to compare the
measured MS/MS spectra against theoretical fragment ion
spectra generated by in silico digestion of protein data-
bases. Comparison of experimental with theoretical spectra
results in a list of possible peptide matches, each with an
associated score that quantifies the quality of the match.
The peptide(s) with the highest score(s) is(are) generally
considered for protein identification. Several of these
search engines have been commercialised (e.g. Sequest,
Mascot or Phenyx), but others are freely available (open
source programs, e.g. XTandem or OMSSA). They usually
agree on 80% of the identifications(29). The two most
established applications are Sequest(30) and Mascot(31).
Identified peptides and proteins can be further validated
by software that applies statistical algorithms to calculate
additional scores and probabilities, thereby distinguishing
correct from incorrect assignments. PeptideProphet and
ProteinProphet from the TransProteomic Pipeline (ISB,
Seattle)(32,33) determine respectively at peptide and protein
level the probabilities of correctness associated with
false discovery rate. These tools provide the researcher
with means to assess the quality of the data in a dataset-
dependent manner and to control the trade-off between
false positives (specificity) and false negatives (sen-
sitivity)(34). The second strategy to elucidate the false-
positive/false-negative relationship relies on a database
search using a target-decoy database(35), which is typically
generated by reversing the sequences of target protein
database. The search is done against the target and the
decoy database and allows the estimation of false positives.
Protein quantification
Once qualitative analysis of a sample is achieved (first
discovery mode, protein catalogue), very often quantitative
information is required to obtain more insight into pro-
teome differences between conditions or over time.
Relative quantification enables the comparison of two or
more biological samples/conditions and the identification
of (candidate) biomarkers, i.e. proteins that are more or
less abundant (up- or down-regulated) in a certain condi-
tion compared to another.
The classical method for relative quantification evolved
from 2D gels: 2D difference gel electrophoresis is charac-
terised by differential labelling of proteins with fluorescent
dyes prior to separation according to isoelectric point and
molecular weight(36). An internal standard is used to match
the protein patterns across gels thereby facilitating gel
alignment, spot matching and quantification. Dedicated
Fig. 1. (Colour online) Classical workflows in MS-based discovery proteomics. Both gel-based and liquid chromato-
graphy (LC) based approaches are represented, with the latter increasingly taking over the proteomics business. ESI,
electrospray ionisation; MALDI, matrix-assisted laser desorption/ionisation.
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software (e.g. Progenesis SameSpots and DeCyder) allow
for gel comparison and spot quantification.
Other procedures for relative quantification of proteins
rely on metabolic or chemical labelling of proteins by
incorporation of stable isotopes (usually 13C or 15N) in the
samples to be compared and quantified at MS level.
A summary of popular chemical labels used for relative
protein quantification is shown on Fig. 2 that depicts a
generic peptide with its side chains and modification
options. Labelling of proteins and peptides is performed by
in vitro chemical or enzymatic derivatisation and include
for example: isotope-coded affinity tag(37), isotope tags for
relative and absolute quantification(38), isotope-coded pro-
tein label(39) or aniline and benzoic acid labelling (40). The
differentially labelled samples are mixed and infused into
an LC-MS/MS instrument. While these techniques invol-
ving labelling are accurate, they need specific sample pre-
paration and involve added costs due to stable-isotope
labelled reagents. In contrast to chemical labelling, stable
isotope labelling by amino acids in cell culture(41) consists
in labelling of proteins already during cell growth and
division by incorporation of labelled amino acids.
Recently, methods for label-free relative quantification
have been developed. In this case, each sample is sepa-
rately analysed by LC-MS/MS and resulting data are pro-
cessed using software designed for LC-MS/MS run
alignment, extraction of peptide intensities and peptide
counts (e.g. Progenesis LCMS, DeCyder MS, SuperHirn,
SpecArray or MSQuant). Currently, two label-free quanti-
fication strategies can be used: (a) measuring and com-
paring the mass spectrometric signal intensity of peptide
precursor ions belonging to a particular protein(64,65); and
(b) counting and comparing the number of fragment spec-
tra identifying peptides of a given protein(66). In compar-
ison with stable isotopes, label-free protein quantification
is simpler to perform; there is technically no limit to the
number of sample/conditions to be compared (except the
analytical capacity of software/computers/servers); and it
can yield an improved proteome coverage with a broader
dynamic range(67). However, label-free proteome compar-
isons are limited to not too complex proteomes, otherwise
the peptide-to-peptide alignment becomes too difficult due
to LC elution and m/z overlaps.
Absolute quantification of proteins relies on the addition
of an internal standard at a known concentration. The
Absolute QUAntification method(68) uses synthetic stable-
isotope labelled proteotypic peptides as internal standards
that are otherwise identical to the peptides to be quantified.
This approach requires preliminary analyses to select
the peptides to be used to quantify the protein(s) of
interest (proteotypic peptides). Recently, the QconCAT
technology has been developed for parallel production
of labelled proteotypic peptides which are then used
in multiplexed quantification assays(69). QconCAT consists
of an artificial gene, inserted into a vector for expression
in Escherischia coli, which is designed to express
Fig. 2. (Colour online) Protein quantification based on chemical stable-isotope labelling. Labels targeting N- and C-termini
are reported in light print, whereas labels targeting side chains of amino acids within a polypeptide are reported in dark print.
Derivatisations occurring at the N-terminus also affect the e-amino group of lysine. For each type of label, a reference is
indicated(37,40,42–63). Adapted from Julka and Regnier(43), authorisation no. 2597551000090.
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artificial proteins comprising a concatenation of proteo-
typic peptides. This latter technology is highly useful for
repetitive, multiplexed analysis, i.e. a protein assay-like
situation.
The systematic large-scale approach for absolute protein
quantification has been referred to as selected-reaction
monitoring or multiple-reaction monitoring(70). This type
of protein quantification is based on the quantification of
relevant proteotypic peptides and is exclusively performed
with triple-quadrupole mass spectrometers. The masses of
the peptides and of their most abundant fragments are
defined in the method and the mass spectrometer only
scans for these as well as for the corresponding stable-
isotope labelled proteotypic peptides. A chromatographic
peak proportional to the peptide amount appears only if
both parent and fragment masses are present (referred to as
one transition). These peaks can then be integrated and the
peptide and protein concentrations can be calculated by
comparison with the internal peptide standard. This method
enables the targeted, multiplexed, high-throughput quanti-
fication of low-abundance proteins in highly complex
mixtures.
Analysis of post-translational modifications:
protein functionality
PTM of amino acids give functionality to the proteins
through the attachment of functional groups such as phos-
phate, carbohydrates, acetate or lipids. PTM play crucial
roles in regulating the biology of the cell since they can
change a protein’s physical or chemical property, activity,
localisation or stability. Some PTM can be added and
removed dynamically as a mechanism for reversibly con-
trolling protein function and cell signalling. Several pro-
teomic techniques have been developed to identify and
quantify PTM and allow the study of modifications such
as phosphorylation, acetylation, glycosylation or lipid
modifications.
Phosphorylation of proteins controls many cellular pro-
cesses such as growth, differentiation, metabolism, signal-
ling and cell death, and is itself regulated by enzymatic
activity (i.e. by kinases and phosphatases). The challenges
of phosphoproteomics lie, as for proteomics, in the com-
plexity, dynamic range and temporal dynamics of protein
isoforms(71). Several methods have been developed to
enrich phosphoproteins and include anti-phosphotyrosine
antibodies(72); immobilised metal affinity chromato-
graphy(73); and chemical modification and strong exchange
chromatography(74). The analysis of phosphorylated pro-
teins has been facilitated by the development of new
fragmentation techniques such as electron capture dis-
sociation(75) and electron transfer dissociation(76,77) that
help identify and determine the location of phosphoryla-
tions that cannot be as efficiently characterised by standard
collision-induced dissociation.
Protein glycosylation is prevalent in proteins that are
involved in mechanisms like cell–cell interactions, immune
system (e.g. antibodies, MHC) or transport (e.g. transfer-
rin). Also, glycoproteins account for a major proportion of
milk and human blood proteomes for which it has been
estimated that 70 and 50% of all proteins are glycosylated,
respectively. There are two types of glycoproteins: (a) N-
glycosylated proteins with carbohydrates linked to the side
chain of the asparagine; and (b) O-glycosylated proteins, in
which carbohydrates are bound to the side chain of serine,
threonine, hydroxylysine or hydroxyproline. The functions
of glycoproteins are still incompletely understood(78). MS
can provide information on molecular mass, composition,
sequence and sometimes branching of a glycan chain(79,80).
As glycoprotein forms are often minor constituents com-
pared to the non-glycosylated proteins, enrichment meth-
ods such as cell surface-capture technology(42) or affinity
capture with lectins(81) have been set-up.
Acetylation is a PTM that has been associated with
several biological processes, especially gene expression
regulation by histones, which pack the chromosomes so
that they fit into the cell nucleus(82). Acetylation usually
occurs at lysines or on N-terminal groups of peptides or
proteins and is involved in the destabilisation of chromatin
and recruitment of effector proteins(83–86). Especially the
mass spectral deciphering of the so-termed and above dis-
cussed histone codes, a key epigenetic mechanism, is
expected to shed light on the phenomenon of metabolic
programming: there is compelling evidence that the human
body retains a memory of environmental, such as nutri-
tional, impacts and may thereby be ‘metabolically
(re)wired’. Such events have been associated with epi-
genetics, of which histone (de)acetylation is a central
mechanism(87). Recently O-aceylated serine and threonine
residues have been identified(88). Acetylation is stable to
peptide fragmentation and can be detected by its charac-
teristic mass shift from unmodified form. Trypsin cleavage
at acetyllysine residues is usually blocked, so the acety-
lated peptides are detected as ‘missed cleavage’ product
when performing database searches(89). Enrichment of
acetylated peptides is difficult and therefore studies have
generally characterised protein acetylation on partially
purified mixtures (e.g. histones). Immunoaffinity techni-
ques have been developed to purify acetylated peptides:
acetyllysine sites were mapped by enriching acetylated
peptides using resin-coupled antibodies to acetyllysine(90).
Lipoproteins are lipid–protein complexes whose primary
function is thought to be transport of cholesterol and other
lipids and that include five protein classes: chylomicrons,
VLDL, intermediate density lipoproteins, LDL and HDL.
Many lines of evidence strongly link them to the immune
system and macrophage biology(91–93). Several approaches
have been developed for lipoprotein isolation(94–97); deli-
pidation(98,99); sample preparation (solubilisation and
digestion)(100–103); and the characterisation of protein
component of lipoproteins using MS(104,105).
Emerging proteomic technologies
The full characterisation of a given proteome remains a
challenge today. This is due to factors such as the large
dynamic range of protein expression, complexity of the
mixture in terms of numbers of proteins, as well as lack of
methods to amplify proteins. However, proteomics is a
rapidly expanding field and new analytical approaches are
emerging.
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Usually, proteomic profiling is done in a data-dependent
acquisition mode in which the most abundant ionised
peptides from each MS scan are selected for subsequent
MS/MS analysis. A data-independent acquisition method,
referred to as Precursor Acquisition Independent From Ion
Count, consists of the acquisition of MS/MS spectra at
every m/z value regardless of whether a precursor ion is
observed or not: precursor ion scans (MS scan) are no
longer conducted(28). This strategy yields better proteome
coverage, higher numbers of identified proteins and
an extended dynamic range compared to the classical data-
dependent method(106).
Imaging MS is a technology enabling the direct exam-
ination of the distribution of biomolecules (e.g. proteins,
peptides, etc) in cells or tissues(107–109). Imaging MS is
principally used for clinical applications(110,111) and bio-
marker discovery in diseased tissue(112,113). In imaging
MS, frozen tissue sections are mounted on a target plate,
covered with a suitable matrix, dried and inserted into a
MALDI-MS for spectra acquisition. The mass spectro-
meter records the spatial distribution of peptides and
proteins by scanning the tissue surface with consecutive
laser shots. Alternatively, in situ tryptic digestion of a spot
on a tissue followed by peptide sequencing of a predicted
fragment by MALDI-MS/MS can be done(114). Specific
methods have been developed for the analysis of formalin-
fixed paraffin-embedded sections(115). Often histological
staining, either on the same section(116) or on a serial sec-
tion(117), is used to guide the placement of matrix and
provides the capability of focusing on areas having a high
content of a cell type of interest.
The trend towards biological analysis at decreasing
scale, ultimately down to an individual cell, continues, and
MS with sensitivity of detecting a few to single molecules
will be necessary. Recently, a prototype for a mass spec-
trometer with single-molecule sensitivity for single-cell
proteomics has been designed(118). Another method for the
analysis of protein complexes in single cells, so-called
visual proteomics, has been developed(119) and consists of
the combination of quantitative MS with cryo-electron
tomography for the detection, counting and localisation of
protein complexes.
Proteomics today: a paradigm shift
A recent publication reviews proteome coverage and
reports on the detection of protein abundance over seven
orders of magnitude with today’s high-end platforms(120).
This impressive power is a combined result of highly
improved mass spectrometric instrumentation and data
acquisition/processing as well as of highly sophisticated
fractionation, enrichment and depletion techniques.
However, given the complexity and dynamics of pro-
teomes, proteomics experiences nowadays a paradigm
shift. Strategically speaking, the original hypothesis-free
discovery workflow is being increasingly complemented or
followed up by either hypothesis-driven analysis or even
by candidate-based targeted analysis and validation: a
recent review puts the discovery, directed and targeted
proteomics approaches into perspective(121). Proteomics
has thereby developed from a pure discovery to a screening
and validation tool. The discovery workflow (or shotgun
approach) aims at identifying large protein sets in a
sample, and can include protein quantification (with or
without prior protein labelling). The directed proteomics
workflow consists of two successive analyses of the same
sample. The first analysis is a survey scan aiming at the
definition of a list of target peptides used for a second
analysis surveying exclusively the peptides of the target
list. This approach allows the quantification of less abun-
dant proteins. Finally, targeted proteomics is a hypothesis-
driven approach focusing on the detection and
quantification of specific peptides associated with the pro-
teins of interest (selected-reaction monitoring or multiple-
reaction monitoring).
The other change of proteomic ‘philosophy’ roots in the
increasing appreciation of peptides as bioactive, health
beneficial food components(122). The analysis of such
peptides requires a different analytical approach because
these entities vary much more in their chemical nature than
classical tryptic peptides generated in shotgun proteomics
workflows for protein biomarker identification: multiple-
processing parameters and digestive enzymes come into
play and these generate not only a large variety in peptide
length, sequence and terminal residues but also a number
of peptide modifications. Moreover, there is only a single
possibility to identify and quantify the native peptide of
interest as such molecule is not one of several representa-
tives of a parent protein, as it is typically the case in
biomarker research. In view of this food peptidome com-
plexity, it becomes evident that proteomic tools must be
further developed and adapted from biomarker to bioactive
research(123).
Proteomics and nutrition: major applications
Several groups including ours have contributed to the
introduction and adaptation of proteomics to the field
of nutrition and health(124–127). Numerous studies have
shown the prominent role of nutrition for maintaining and
improving health. In this view, proteomics has been
deployed in fields such as characterisation of bioactive
proteins and peptides(128); elucidation of immune-related
disorders(129,130); investigation of metabolism-related dis-
orders(131); dietary intervention studies for recov-
ery(132,133); and mechanistic elucidation of nutrient
action(134). The following selected citations cover topics
from characterisation of the food matter itself via investi-
gation of health-related food benefits to understanding
disease-related mechanisms.
Protein and peptides as food ingredients
Milk. Milk is an essential component for infant nutrition
since it represents the major source of feeding for new-
borns and infants(135). It is a rich source of functional
peptides and proteins beneficial for human health. Exten-
sive characterisation of milk from different species has
been reported(135–139) and the composition of milk in terms
of major proteins, lipids and carbohydrates has been
established.
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Technical milk fractionation by successive centrifuga-
tion steps yields three major fractions: caseins, whey and
milk fat globule membrane (MFGM)(140). Each of these
fractions contains different protein functionalities which
have been studied using proteomics.
The whey protein fraction is dominated by a small
number of abundant proteins which constitute over 80% of
its protein content(141). In particular, b-lactoglobulin alone
constitutes 50% of whey. In consequence, further fractio-
nation was necessary to identify less abundant proteins.
A gel-based approach(142) enabled the identification of a
large number of minor whey proteins, for example, a
cluster of osteopontin peptides suggesting novel bioactiv-
ities. Another study, based on the use of electrospray
ionisation and MALDI ionisation sources in parallel,
allowed enhanced protein identification(143): a total of
thirty-nine bovine milk proteins were identified with a high
degree of confidence.
The MFGM is a milk fraction rich in bioactive proteins.
A qualitative and a quantitative proteomic profiling of two
MFGM enriched milk fractions, whey protein concentrate
and buttermilk protein concentrate was reported by our
group(144): using an LC-MS/MS-based shotgun approach,
we could reveal the presence of 244 proteins in whey
protein concentrate and 133 in buttermilk protein, respec-
tively, and provided an extensive characterisation of the
protein content in those two fractions. Then, a label-free
profiling approach delivered semi-quantitative comparison
of both fractions and yielded protein fingerprints. Finally,
we performed absolute quantification by combining
stable-isotope dilution and multiple-reaction monitoring
in order to precisely quantify seven major MFGM
proteins.
PTM of milk proteins (phosphorylation and glycosyla-
tion) were investigated by mass spectrometric technolo-
gies. Different approaches, from 2D gels to LC separation,
were used to determine the phosphorylation pattern of
caseins in human, bovine, equine, goat and buffalo
milk(144–148). In particular, a study of buffalo skim milk,
whey and MFGM reported phosphorylation data on caseins
providing scientific basis to coagulation/cheese making
processes used in dairy productions(149). Glycosylation of
milk proteins has also been investigated by MS(150,151). It
is estimated that, in milk, glycoproteins may account for
up to 70% of the total protein content, whereas it is about
50% for all human proteins(136). Indeed, the most abundant
proteins in milk including casein, lactoferrin and the Ig are
all glycoproteins. The position and extent of glycosylation
of these proteins affect their degradation, the resulting
released peptides and glycopeptides and the function they
provide. Indeed, there is emerging evidence for the invol-
vement of milk glycoproteins in infant protection against
pathogen infection(136,152–154). For example, the glycopro-
teins in MFGM are considered to operate as specific bac-
terial and viral ligands preventing the pathogens from
binding to the intestinal mucosa of the infants(155–157).
Hydrophilic interaction chromatography was used to
enrich glycoproteins from human milk(158) and enabled
the identification of thirty-two glycoproteins and sixty-
three N-glycosylated sites. Immunocompetent complexes,
membrane fat globule enzymes, proteins involved in lipid
metabolism and specific receptors figured among these
glycoproteins.
Lactoferrin is a major Fe-binding mammalian milk gly-
coprotein that impacts the defence system of the human
host: it can for example prevent microbial growth, by
direct interaction with the membrane of Gram-negative
bacteria(159). Lactoferrin and its derived peptides are also
known to influence cytokine production in cell cultures
experiments mimicking immune and inflammatory
processes(160).
The potential benefits of food-derived peptides in terms
of reduced risk of CVD have been reviewed(134): the
favourable properties for blood pressure, oxidative stress,
homoeostasis, appetite and lipid metabolism have been
discussed. Also, the benefits of lactotripeptides on hyper-
tension are well established: the tripeptides VPP (Valine–
Proline–Proline) and IPP (Isoleucine–Proline–Proline)
form upon fermentation of a milk product by Lactobacillus
helveticus and Saccharomyces cerevisiae. When this
fermented milk was fed to rats, the animals’ blood pressure
was lowered(161).
Probiotics. Probiotics are live micro-organisms which,
when administered in adequate amounts, confer a health
benefit on the host(162). Probiotics are commonly consumed
as part of fermented foods with specially added active
live cultures, such as in yoghurt or dietary supplements.
Lactic acid bacteria and bifidobacteria are the most com-
mon types of micro-organisms used as probiotics. While
their health benefits have been documented in clinical
trials, their mechanisms of action are still poorly under-
stood. The benefits of probiotics include stimulation of
the mucosal immunity, reduction of mucosal alterations
and interaction with mediators of inflammation(163,164).
Numerous proteomic studies aim at characterising the
microbial proteomes and at understanding how probiotics
interact with the gastrointestinal tract.
Bacteria release a wide range of compounds into their
environment in order to communicate and coordinate their
activities. Recently, it was shown that the co-culture of
two Bifidobacteria strains (Bifidobacterium longum and
Bifidobacterium breve) induced changes in each bacteria’s
proteome(165). Indeed, 2D gel analysis followed by
LC-MS/MS analysis resulted in the identification of
sixteen proteins, whose abundances were drastically
changed when bifidobacteria were grown in co-culture
compared to mono-culture. Differentially regulated pro-
teins were grouped into ribosomal proteins and proteins
involved in carbohydrate metabolism, gene regulation, cell
envelope biogenesis as well as transport.
Another study investigated the surface-associated pro-
teins from the probiotic Lactobacillus plantarum(166). Cell
surface proteins were migrated on one-dimensional
gels and identified using LC-MS/MS. A total of twenty-
nine proteins were identified and many of these proteins
had previously been described of being capable to bind
components of the human intestinal mucosa. In a related
investigation, three different L. plantarum strains showing
different adhesion rates were analysed using pro-
teomics(167). Several proteins, previously reported to be
involved in bacterial adhesion, were found to be
more abundant in the cell wall proteome of the most
Nutriproteomics: technologies and applications 357
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0029665111000528
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 17:58:04, subject to the Cambridge Core terms of use, available at
P
ro
ce
ed
in
gs
o
f
th
e
N
u
tr
it
io
n
So
ci
et
y
highly-adhesive strain (elongation factor EF-tu (Elongation
Factor Tu), GroEL (60 kDa chaperonin), DnaK (Chaperone
protein Dna K) and glyceraldehyde-3-phosphate dehydro-
genase). The association of proteomic profiles with parti-
cular probiotic properties opens the way for the selection
of probiotics with specific, targeted benefits.
Allergens: protein and peptides as food-derived causes
of hazard
Food allergies arise from the intake of allergenic food
components, which can induce a response from the
immune system and lead to clinical symptoms ranging
from mild to life threatening(168). The prevalence of food
allergy is rising; indeed 2% of adults and 5–8% of children
in industrialised countries are affected(169–171). Over 180
protein allergens have been identified so far, the major
ones occurring in common foods such as cow’s milk, egg,
peanut, soyabean, wheat, fish and tree nut(172). Sensitive
consumers have to be protected from undesirable allergic
reactions and, therefore, proteomic methods have been
developed for accurate allergen identification and quanti-
fication(130,172,173).
The classical proteomic strategy to identify food aller-
gens consists of separating food proteins on 2D-PAGE,
followed by electro-transfer onto a nitrocellulose
membrane and subsequent IgE reactive protein detection
by IgE immunoblotting using sera from allergic patients.
This method was used to study allergens in wheat(174,175),
apple(176), maize(177) or sesame seeds(178). A systematic
proteomic analysis of rice (Oryza sativa) leaf, root and
seed using 2D gels followed by MS/MS allowed for the
detection and identification of more than 2500 proteins(179)
including several previously characterised allergenic pro-
teins. The 2D difference gel electrophoresis method was
also used to study several peanut varieties in order to show
their low content of major allergens(180). Recently, a
method based on spectral counting was developed and
successfully applied to the analysis of transgenic peanut
lines containing reduced levels of certain major aller-
gens(181).
Biomarkers: proteins and peptides as indicators of health
and disease
Biomarkers are measurable indicators of different stages in
a biological process, ranging from healthy functioning via
deviation from such healthy equilibrium to disease onset
and development(182). Proteins and peptides, which are the
main effectors in the body, can be used as such bio-
markers. In practice, biomarkers are used for diagnostics,
for prognostics, and to measure bioefficacy of nutrients in
an intervention study.
Intestinal health and disease: Inflammatory bowel dis-
ease as an example. Inflammatory bowel diseases (IBD),
including ulcerative colitis and Crohn’s disease, are
chronic, heterogeneous and multi-factorial inflammatory
disorders of the gastrointestinal tract(182,183). Proteomic
investigations of the intestinal tissue of patients v. controls
have the potential to deliver insights into gut dysfunction
and may provide disease biomarkers.
A study of protein expression in intestinal epithelial
cells led to the characterisation of changes in protein
profiles of patients with Crohn’s disease or ulcerative
colitis compared to controls(184). 2D-PAGE followed by
MALDI-time-of-flight protein identification delivered the
identification of nine proteins significantly different in IBD
patients (e.g. Rho GDI alpha (Rho GDP-dissociation inhi-
bitor 1), L-lactate dehydrogenase A, etc.). In ulcerative
colitis patients, forty differentially expressed proteins were
identified among which thirteen were associated with
energy metabolism, which is in line with chronic intestinal
inflammation being characterised by energy deficiency and
alteration of the oxidative metabolism of epithelial
cells(185,186).
A related study with 120 serum samples collected from
four patients groups (Crohn’s disease, ulcerative colitis,
inflammatory controls, healthy controls) was performed to
identify serum IBD biomarkers(187): four new serum bio-
markers were identified, namely PF4 (platelet factor 4),
MRP8 (migration inhibitory factor-related protein 8), FIBA
(fibrinogen alpha chain) and Hp alpha 2 (haptaglobin
alpha 2). Another study focused on stool analysis: apart
from S100A8 and S100A9 already associated with IBD,
S100A12 was identified a possible new IBD marker(188).
However, the aetiology of IBD is still poorly charac-
terised. A major symptom of IBD comprises malnutrition
since inflammation of the gastrointestinal tract perturbs
normal food intake and nutrient absorption(189,190). The
mechanisms involved in malnutrition include decreased
food intake, malabsorption, increased nutrient loss,
increased energy requirements and drug–nutrient interac-
tions. In consequence, nutrition aspects play important
roles in IBD and complement drug treatment. Adequate
food intake is important for treatment, remission, remission
maintenance, relapse prevention and prevention of IBD.
Conclusions and outlook
By balancing their diet, consumers want to optimise some
health aspects without compromising others. Holistic and
integrative approaches are therefore primordial. Proteomics
is a central platform in nutrigenomics, which attempts to
holistically understand how our genome is expressed as a
response to diet. From a molecular perspective, nutritional
proteomics covers two dimensions: characterisation of
food proteins and peptides; biomarker as well as bioactive
discovery and quantification. Nutritional proteomic bio-
markers must be interconnected with other genomic and
genetic markers: nutrigenetics investigates our genetic pre-
disposition and susceptibility towards diet; epigenetics
encompasses DNA sequence-unrelated biochemical modi-
fications of both DNA itself and DNA-binding proteins
and appears to provide a format for metabolic program-
ming. Proteomics plays a key role here, too, as it can
address PTM (e.g. acetylation) of DNA-packaging proteins
and thereby help decipher the so-termed histone code.
Nutrition is still an expanding field for proteomics
compared to well-established clinical and medical appli-
cations. The success of proteomics in nutrition and health
will depend on multiple factors. The proteomic technology
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per se will benefit from ever improving protein/peptide
separation, depletion and enrichment on the one hand and
more sensitive and specific mass spectrometers on the
other hand. The second area of platform-related improve-
ments is bioinformatics with rapidly improving tools to
assess data quality and to convert data into interpretable
information. The third room for improvement concerns
the analytical strategy: focusing on proteome subsets – be
it at the level of cell organelles, protein subclasses,
the mass spectral level (targeted proteomics, gas-phase
fractionation) – will provide deeper insights into molecular
networks.
Apart from this expected progress at platform level,
the technology will increasingly benefit from its cross-
correlation with gene expression analysis and metabolite
profiling. An option of addressing the interrelated timing of
gene and protein expression is the investigation of protein
turnover at proteomic scale but single-protein resolution,
i.e. interpreting protein abundance changes as a result of
both protein synthesis and degradation rather than taking
proteomic snapshots.
In a nutshell, proteomics in nutrition delivers both bio-
markers and bioactives. In this sense, proteomics will
continue to drive (nutritional) systems biology, as it not
only can identify and quantify the ‘molecular robots’ that
do all the work in biological systems but also can map the
networks of their physical interactions, between each other
and with DNA, nutrients, drugs and other small molecules.
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